Ardelyx (NASDAQ:ARDX) Receives Overweight Rating from Piper Sandler

Piper Sandler reissued their overweight rating on shares of Ardelyx (NASDAQ:ARDX – Free Report) in a report released on Friday morning, Benzinga reports. The firm currently has a $15.00 target price on the biopharmaceutical company’s stock. ARDX has been the topic of a number of other research reports. SVB Leerink began coverage on shares of […]

Related Keywords

United States ,Piper Sandler ,Michael Raab ,Elizabetha Grammer ,Leerink Partnrs ,Newbridge Financial Services Group Inc ,Highmark Wealth Management ,Jump Financial ,Citigroup ,Sherbrooke Park Advisers ,Ardelyx Company Profile ,Ardelyx Inc ,Securities Exchange Commission ,Investment Consulting Inc ,Free Report ,Moderate Buy ,Get Free Report ,Exchange Commission ,Mark Wealth Management ,Park Advisers ,Newbridge Financial Services Group ,Ardelyx Daily ,